/
Metabolic & Endocrine
Type 2 Diabetes Mellitus
81
Pipeline Programs↗
87
Active Trials↗
103
Companies Involved↗
Type 2 Diabetes Mellitus is a moderately active landscape with 81 programs across 103 companies. The most active players are Gan & Lee Pharmaceuticals., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hanmi Pharmaceutical Company Limited. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical53
Phase 211
Phase 314
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
72 of 75 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 75 classified programs, each share of the total. Modality classified for 98% of 81 pipeline programs.
Analysis
Trial Status
1,035
clinical trials
Completed768 · 74%
Terminated83 · 8%
Unknown status76 · 7%
Recruiting36 · 3%
Not yet recruiting30 · 3%
Withdrawn21 · 2%
Other21 · 2%
Clinical Trials
Trial Activity
1035 trials
Page 1 of 69
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)